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Abstract
Background—Few studies report the effectiveness of trivalent inactivated influenza vaccine 
(TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a 
prospective surveillance platform, this study reports the first such estimate from a well-defined 
ethnically diverse population in New Zealand (NZ).
Methods—A case test-negative study was used to estimate propensity adjusted vaccine 
effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any 
age requiring hospitalization with a history of a fever or a measured temperature ≥38°C and cough 
and onset within the past 7 days, admitted to public hospitals in Central, South and East Auckland 
were eligible for inclusion in the study. Cases were SARI patients who tested positive for 
influenza, while non-cases (controls) were SARI patients who tested negative. Results were 
adjusted for the propensity to be vaccinated and the timing of the influenza season
Results—The propensity and season adjusted vaccine effectiveness (VE) was estimated as 37% 
(95% CI 18;51). The VE point estimate against influenza A (H1N1) was higher than for influenza 
B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 
51% (95% CI 28;67) in patients aged 18-64 years but only 6% (95% CI -51;42) in those aged 65 
years and above.
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Conclusion—Prospective surveillance for SARI has been successfully established in NZ . This 
study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV 
against hospitalisation for laboratory-confirmed influenza.
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Introduction
Influenza continues to cause a significant burden of illness in adults and children [1, 2] 
despite vaccines having been used internationally for more than 60 years and being 
recommended by the World Health Organization [3]. Estimates of efficacy (from trials) and 
effectiveness (from observational studies) for seasonal trivalent inactivated vaccine (TIV) 
have been variable. An umbrella review of meta-analyses of community studies from 2005 
to 2011 concluded that protection against laboratory-confirmed influenza (largely mild 
disease) by TIV ranged from 59-65% with estimates being similar in working age adults and 
children aged 2 years and above [4]. There have been too few trials in children under 2 years 
for accurate estimates of efficacy in this age group [5, 6], although influenza vaccines are 
generally considered to be less effective in young influenza-naïve children and observational 
studies provide a range of effectiveness estimates from zero to approximately 60% 
protection [7-9]. While studies specifically of older adults are less common, vaccine 
effectiveness (VE) has been reported to be as high as 57% in adults over 70 years [6]. 
However significant variability by season is acknowledged [10] and increasing 
immunosenescence and the presence of comorbidities are likely to reduce effectiveness [6].
Results are more limited when reviewing protection against influenza-confirmed 
hospitalisation. No trials address this outcome. Estimates from observational studies include 
no protection by TIV against laboratory-confirmed influenza [11] to a protective range of 
49% to 61% in adults [12-14]. Pooled European data for VE against A(H3N2) during 
2011/2012 gave a point estimate for the target groups for vaccination of 29% with wide 
confidence intervals[15].
The antigenic composition of influenza vaccines is reviewed annually to predict the best 
match for a constantly evolving virus. The impact of vaccination is expected to be higher in 
the presence of a good antigenic match, although significant effectiveness has been shown 
even in seasons when the circulating strain is not a good match[16, 17].
In New Zealand (NZ) seasonal unadjuvanted TIV is offered annually free of charge to all 
adults aged 65 years and over, pregnant women and all those over 6 months of age with 
chronic medical conditions that are likely to increase severity of infection. The vaccines are 
also available from early March on the private market for all others over 6 months of age. 
The influenza season usually occurs between early May and late September.
Using a case test-negative design we aimed to estimate the effectiveness of seasonal TIVs in 
preventing hospitalised laboratory-confirmed influenza in persons aged at least 6 months 
who were admitted with a febrile respiratory illness to public hospitals in Central, South and 
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East Auckland between April 2012 and February 2013. The study reports results from the 
first year of a five year SHIVERS (Southern Hemisphere Influenza Vaccine Effectiveness, 
Research and Surveillance) project.
Methods
Ethics approval for the study was obtained from the Northern A Health and Disability Ethics 
Committee (NTX/11/11/102 AM02).
Study Design
We used the standard case test-negative design[18] and a similar analytic approach to a 
previous study of hospitalised patients, with adjustment for the propensity to be vaccinated 
[13]. From 30 April 2012 to 28th February 2013 we attempted to enrol all individuals aged 6 
months and older who were hospitalized with a severe acute respiratory illness (SARI). 
Based on the World Health Organization definition, this was defined as a patient requiring 
hospitalization with a patient-reported history of a fever or a measured temperature ≥38°C, 
cough and onset within the past 7 days [19].
A confirmed case of hospitalised influenza was defined as a SARI patient with a positive 
laboratory result for any influenza virus detected by real time reverse transcription 
polymerase chain reaction (RT-PCR) or viral isolation, while non-cases (controls) were 
those who tested negative to all influenza viruses.
Eligible patients were those admitted to the public hospitals Middlemore, Kidz First 
Children's, Auckland City and Starship Children's which together serve a population 
catchment of approximately 838,000 people in Central, South and East Auckland. 
Recruitment was undertaken by trained research nurses. The nurses recruited patients during 
the day and screened all overnight admissions of febrile patients with respiratory symptoms 
daily from Monday to Saturday. Sunday admissions were captured on Mondays if the 
patients were still hospitalized.
All identified SARI cases who gave verbal consent completed a case report form, 
administered by a research nurse, and provided a nasopharyngeal swab or aspirate for 
influenza testing by RT-PCR and/or viral isolation.
Excluded from the analysis were patients transferred from another hospital, children under 6 
months of age, patients who had not provided consent, patients with incomplete data for 
vaccination status or age, or patients who were swabbed more than 7 days after the onset of 
symptoms. At the end of the season, people with multiple SARI hospitalisations were 
excluded if their vaccination status differed between hospitalisations, otherwise the first 
influenza positive admission was used. Only the first hospital admission was used if a 
person had multiple admissions but no influenza positive admission.
Participant information
Demographic data on all cases and non-cases included age; sex; ethnicity (Māori , Pacific 
Islander, Asian, NZ, European or other); and income, with low income defined as a 
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household that received either a government benefit or held a community services card. The 
age data were cross validated with hospital held electronic data. Clinical information was 
obtained from both the case report form and electronic data extraction from hospital 
databases. This included clinical symptoms and signs; influenza vaccination status recorded 
on the case report form; smoking status; body mass index based on either measured weight 
and height or a visual estimation by the research nurses using the categories obese, 
overweight, normal weight, underweight or unsure; a patient or caregiver reported measure 
of dependence, assessing requirement for assistance with normal activity or full dependency 
on nursing care; a simple frailty measure based on use of long term oxygen; a history of 
chronic medical conditions; and a self-defined health status score using the general health 
question from the SF36 [20] and combining fair or poor versus all others. The SF-36 is a 
generic measure using a multi-purpose, short-form health survey that measures a functional 
health and well-being score.
The presence of any chronic condition was defined as at least one of the following: asthma, 
with the need for preventative therapy; diabetes; chronic pulmonary disease (COPD); other 
chronic lung disease; cardiac disease; cerebrovascular disease; moderate to severe cognitive 
impairment; other chronic neurological disease; psychiatric disorder (psychotic or major 
affective disorder); current alcohol or drug dependence; active cancer (excluding non-
invasive skin cancer); immune deficiency condition (including asplenia, HIV/AIDS); 
immune suppressive treatment; chronic renal disease; or chronic liver disease (including 
cirrhosis, chronic hepatitis, transplant). The covariate for co-morbidity was a binary variable 
coded as yes/no.
Vaccination status was recorded as fully vaccinated if the patient or caregiver reported 
influenza vaccination given during the current season at least 14 days prior to the onset of 
symptoms for which they were hospitalised. All children less than 9 years of age were 
recorded as fully vaccinated if they had received a vaccination in the season at least 14 days 
prior to onset of symptoms, and had ever received an earlier vaccine at least one month prior 
to the current vaccine. Children under 9 years of age who had received only one dose of 
vaccine in the season and no previous vaccine were considered partially vaccinated but were 
analysed as nonvaccinated.
Two commercial vaccine products were available on the NZ market in 2012: Fluarix® 
(GlaxoSmithKline) approved for used in people 6 months and over, and Fluvax® (bioCSL) 
approved for use in people aged 5 years and over, but recommended to be used with caution 
in children aged 5-8 years. Both vaccines contained A/California/7/2009 (H1N1)-like strain, 
A/Perth/16/2009 (H3N2)-like strain and B/Brisbane/60/2008-like strain.
Laboratory Methods
Nasopharyngeal swabs were collected with a COPAN flocked swab and transported in viral 
transport medium (VTM) at 4°C. Nasopharyngeal aspirates and other respiratory samples 
were collected according to hospital standard operational procedures. Respiratory samples 
were tested using the United States Center for Disease Control and Prevention real time RT-
PCR protocol [21] at Auckland District Health Board Laboratory and the AusDiagnostic 
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PCR protocol at the South Auckland District Health Board laboratory [22]. All influenza 
positive PCR cases were forwarded to the National Influenza Centre on a weekly basis for 
antigenic typing. RT-PCR assays detected influenza virus types A and B and subtyping was 
performed for A subtypes. A small proportion of cases (8.5%) were subjected to viral 
isolation by inoculation into Madin-Darby canine kidney (MDCK) cells.
Statistical analysis
Characteristics of patients who were influenza positive and negative were compared using 
univariate χ2-tests. Patients at higher risk of an adverse outcome from influenza infection, 
and for whom the vaccine is provided at no charge, may be more likely to be vaccinated. We 
allowed for this by using a multivariate logistic model to calculate the propensity to get 
vaccinated, given the range of patient characteristics listed in Table 1. The results from the 
propensity model are presented as odds ratios (OR) and were used to adjust the VE estimate.
In the primary analysis VE was defined as 1-OR with the OR derived from logistic 
regression models where influenza was the outcome variable. We calculated the crude VE 
adjusting only for the timing of the admission relative to the influenza season and the 
adjusted VE which included both the timing of the admission and a term derived from a 
cubic spline of the fitted values of the propensity model. A cubic spline was used as 
propensity was not linear with respect to influenza status. This approach has previously been 
used by Talbot et al. [13].
The season was defined to include continuous weeks with at least two laboratory-confirmed 
influenza cases. It began on week 5 of the study (May 29, 2012) and ended on week 24 
(October 22, 2012). We present a summary VE estimate against all influenza infections and 
separate stratified estimates for three age ranges (0 to 17, 18 to 64 and 65 and over) and 
influenza A(H1N1)pdm09, A(H3N2) and influenza B. VE estimates for types and subtypes 
used cases positive for the specific type or subtype compared with influenza negative non-
cases.
For all patient characteristics, other than age and vaccination status, missing values were 
imputed as the modal baseline case of non-Māori, non-Pacific ethnicity, female, not low 
income, not pregnant, non-smoker, without chronic disease, not obese, with self-rated health 
average or better, not on long term oxygen use and living without assistance. Sensitivity 
analyses were performed excluding individuals with missing data and samples tested only 
by viral isolation. We also compared results from the propensity adjusted model with an 
epidemiological model where the same covariates were forced into a logistic regression 
model with influenza as the outcome and vaccination as the primary exposure variable. We 
further constructed a statistical model where only the variables in the epidemiological model 
that were significant at the level of p<0.05 in univariate analysis were included in the 
logistic regression model. Assuming VE was 50% and vaccine coverage in the controls was 
20%, we estimated 207 cases gave 80% power to detect a significant protection due to 
vaccine.
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Results
Case selection and exclusion/inclusion criteria are shown in Figure 1. Of the 6373 
admissions screened, 2682 (42%) met the definition of SARI. After exclusions for lack of 
consent (n=224), no record of vaccination history (n=300), no recorded date of birth (n=1), 
aged less then 6 months (n=226) or no laboratory results available (n=88), a total of 1843 
admissions remained, of whom 382 (21%) were influenza positive (Figure 2) . Excluding 
multiple admissions, 1773 SARI patients were included in this analysis. Of the 379 (21%) 
who were inflenza positive, 123 (32%) were vaccinated and, of the 1394 who tested 
negative for influenza, 534 (38%) were vaccinated (Figure 1). There were 88 samples where 
no laboratory results were available because we were unable to obtain or analyse the sample. 
Most (n=49) were unvaccinated children under the age of 5 years and, of the remaining 39 
more than five years of age, 14 (36%) were vaccinated.
The 379 influenza positive case and 1394 influenza negative non-cases were compared 
across a range of patient characteristics. Patients who were. Influenza positive were more 
likely to be unvaccinated, younger, of Pacific ethnicity, not on long term oxygen, to require 
assistance with daily living and to be admitted during the influenza season. There were no 
statistically significant differences by gender, income, pregnancy, smoking, presence of a 
chronic disease, obesity or self-rated health (Table 1). The adjusted odds ratios for the 
association of various patient characteristics with likelihood of vaccination showed that 
older age groups, those with chronic diseases or on long term oxygen were more likely, and 
smokers were less likely, to be vaccinated (Table 2). In contrast, there was no statistically 
significant difference in the likelihood of vaccination by ethnicity, gender, income, 
pregnancy, obesity, self-rated health, assisted living or the timing of the admission relative 
to the influenza season (Table 2).
Vaccine Effectiveness
The VE against any influenza infection and adjusted only for season was 25% (95% 
confidence interval 4;41). After adjusting for the propensity to be vaccinated the estimated 
VE was 37% (18;51). In the sensitivity analysis, the VE against any influenza infection 
estimated from the epidemiological model was 40% (19;55) and from the statistical model 
was 41% (22;56). There was no significant change to these estimates when ommitting 
patients with missing values or for whom influenza was tested only by viral isolation (data 
not shown). VE for patients aged 18-64 years was 51% (28;67) with a point estimate of 69% 
in patients aged 0-17 years but only 6% in patients aged at least 65 years . The VE estimate 
against influenza A (H1N1) was higher than the point estimates for influenza B and 
influenza A (H3N2) but confidence intervals were wide and overlapping (Table 3). With 27 
cases and 278 non-cases in patients aged at least 65 years, the propensity adjusted VE 
against influenza A(H3N2) was 35% (−49; 72).
The vaccine formulations used in New Zealand in 2012 included a strain that matched the 
circulating 2009 A(H1N1)pdm09 strain which represented 10% (247/2425) of all viruses 
detected in NZ in 2012. VE against this strain was 52% (23;71). Influenza B virus 
represented 13% (306/2425) of all viruses detected with both B lineages co-circulating. The 
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2012 vaccine strain was a B/Victoria lineage. More B/Yamagata lineage viruses (84%, 
99/118) than B/Victoria lineage viruses (16%, 19/118) were detected. VE against influenza 
B was 45% (9;66). There were too few data to calculate B lineage specific VE estimates 
Influenza A(H3N2) viruses represented 65% of all viruses detected. Most A(H3N2) viruses 
had drifted away from the A/Perth/16/2009 vaccine strain (data not shown). VE against 
A(H3N2) was 25% (−8;48).
Discussion
This study has four important findings. Firstly, we found that 21% of SARI admissions in 
Auckland during the study period were due to influenza. Secondly, VE against 
hospitalisation for the 2012 season was relatively low with a point estimate of 37%. Thirdly, 
while underpowered to show age effect, vaccination appeared less effective in patients aged 
at least 65 years although this may be an effect of response to the circulating influenza type 
rather than an age effect, and lastly VE varied by influenza type and subtype. Specifically, 
older people did not appear to be significantly protected against hospitalisation for infection 
with influenza A(H3N2). Studies of hospitalised patients using a laboratory-confirmed 
endpoint have reported a wide range of results for VE. Our point estimate of 37% is within 
this range. Using a test negative design over two seasons, Puig-Barbera and colleagues were 
unable to show a significant protective effect from seasonal vaccine for adults, although 
adjusted VE for monovalent A(H1N1) pandemic provided high protection [11]. Talbot et al 
studied adults 50 years and older hospitalised in the US and found a VE estimate of 61% 
(18;82) [13]. A test negative case-control in the 2010/2011 season in Spain showed VE of 
58% (20;89) against hospitalised laboratory-confirmed influenza in adults aged between 52 
and 84 years, although VE rose to 68% (13;77) for those who had received both the seasonal 
and pandemic A(H1N1) monovalent vaccine[23]. A more recent Spanish study of 
hospitalised patients using three different control groups showed similar vaccine 
effectiveness of 60% for all ages but higher effectiveness (89%) against severe cases[24]. In 
the southern hemisphere, Cheng et al reported VE against influenza hospitalisation of 49% 
(13;70) for adults aged 18 years and older in the 2010 Australian influenza season[14].
The lower VE results from our study are not dissimilar to a population-based study by 
Baxter et al to determine the association between hospitalization and prior vaccination over 
an 11 year period. The study examined VE within the season, compared to outside the 
season, using a “difference-in-differences” approach [25]. Estimated reduction in influenza-
attributable hospitalisations from influenza vaccination were 28% (9;30) for adults 50-64 
years and 48% (12;26%) for those 65 years and over.
Similar to our study findings low to moderate effectiveness and variations by age and type/
subtype have been identified as challenges with seasonal influenza vaccines [26]. In the 
2012 Danish influenza season no significant protection against influenza-confirmed 
hospitalisation for patients aged 65 years and older was seen for A(H3N2), whereas VE in 
the same age group for influenza B was 69% (26;87)[27].
Turner et al. Page 7
Vaccine. Author manuscript; available in PMC 2015 October 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Strengths and Limitations
The strengths of this study include the establishment of an effective influenza surveillance 
system in New Zealand, using RT-PCR-confirmed hospitalised influenza as the outcome 
measure. Estimating VE against the serious outcome of hospitalisation may have more 
relevance for public health policy than estimation of protection against milder disease that is 
managed in the community. The recruitment process selected potential SARI cases from a 
full range of respiratory illness categories including both acute and chronic illnesses. 
However we would not have captured influenza related hospitalisations that presented as a 
non-respiratory illness such as patients with exacerbation of cardiovascular disease.
We collected a large range of variables that could be included in the statistical model. 
However adjustment for the differences between vaccinated and unvaccinated study 
participants may have differed in ways that had not been considered or were difficult to 
measure. Furthermore, little is known about the 220 individuals with SARI who did not give 
informed consent. This was mostly due to language barriers. It is possible that people for 
whom English is not a first language may have greater challenges in accessing health care 
services and therefore more likely to be under-vaccinated. A further study weakness was the 
record of vaccination status, based only on patient recall. However self-report has been 
shown to be generally accurate in hospitalised elderly[28]. Future studies will use verified 
vaccinations based on provider records. The influenza laboratory test has some limitations. 
The clinical sensitivity for all targets (influenza A, influenza B, A(H1N1)pdm09 and 
A(H3N2) is greater than 93% and the clinical specificity for all targets is greater than 90% 
[29]. Any resulting misclassification can be expected to have biased our estimates towards 
the null [30] and this could be more likely in hospitalised patients where an upper 
respiratory tract specimen is used to diagnose lower respiratory tract disease.
In summary, we have established prospective surveillance for SARI in New Zealand and 
have shown low to moderate protection from TIV in influenza-positive SARI patients in the 
2012 influenza season. In future years, surveillance will include patients seen in sentinel 
general practices as well as those admitted to hospital and we will be able to provide a more 
complete picture of the burden of influenza in a well-defined ethnically diverse community. 
We will also be able to compare the effectiveness of influenza vaccines in preventing 
attendance at a general practitioner for laboratory-confirmed influenza with effectiveness 
against the, possibly more policy relevant, outcome of admission to hospital.
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Highlights
• This study adds to the limited research on VE to influenza from the southern 
hemisphere
• TIV vaccines show low to moderate protection against hospitalisation for 
laboratory confirmed influenza in 2012.
• VE varied by influenza type and subtype
• Vaccination appeared to be less effective in patients aged 65 years and older
• Older people did not appear to be significantly protected against infection with 
influenza A(H3N2)
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Figure 1. 
Flowchart of all selected, recruited, eligible, complete and unique admissions for VE 
analysis
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Figure 2. 
Weekly SARI cases including influenza PCR positive cases during 30 April 2012 to 28 
February 2013
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Table 1
Patient characteristics and their association with influenza status
Influenza Positive n=379 Influenza Negative n= 1394 P Value
Vaccinated 123(32.5%) 534(38.3%) 0.04
Median Age 44 years 41 years 0.10
Age Group 0 to 5 67(17.7%) 376(27.0%) <0.01
6 to 17 23(6.1%) 61(4.4%)
18 to 45 94(24.8%) 264(18.9%)
46 to 64 86(22.7%) 269(19.3%)
65 to 79 66(17.5%) 278(19.9%)
80+ 43(11.4%) 146(10.5%)
Male 177(46.7%) 693(49.7%) 0.33
Maori 53(14.0%) 253(16.9%) <0.01
Pacific 138(36.4%) 377(27.0%)
Other 188(49.6%) 764(56.1%)
Low Income 219(57.8%) 830(59.5%) 0.58
Pregnant 8(2.1%) 13(0.9%) 0.11
Smoker 50(13.2%) 172(12.3%) 0.72
Chronic Disease 242(63.8%) 851(61.0%) 0.35
Obese 52(13.7%) 194(13.9%) 0.99
SF36- (poor or fair) 70(18.5%) 172(19.1%) 0.82
Long Term Oxygen use 3(0.8%) 37(2.6%) 0.05
Dependence 271(71.5%) 792(56.8%) <0.01
Pre Season 3(0.8%) 116(8.3%) <0.01
Peak Season 353(93.1%) 969(69.5%)
Late Season 23(6.1%) 309(22.2%)
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Table 2
Patient characteristics and their association with influenza vaccination status*
OR 95% lower confidence interval 95% upper confidence interval P
Age 0 to 5 0.16 0.09 0.28 <0.01
Age 6 to 17 0.36 0.19 0.69 <0.01
Age 18 to 45 0.5 0.35 0.7 <0.01
Age 65 to 79 2.26 1.64 3.13 <0.01
Age 80 2.37 1.58 3.54 <0.01
Maori 0.87 0.61 1.23 0.43
Pacific 1.03 0.77 1.37 0.83
Male 0.98 0.77 1.23 0.85
Low income 1.2 0.93 1.54 0.16
Pregnant 0.77 0.25 2.43 0.66
Smoker 0.7 0.5 0.99 0.04
Chronic 2.59 1.91 3.5 <0.01
Obese 0.88 0.64 1.22 0.45
Sf36- 1.05 0.79 1.4 0.72
Long term oxygen use 5.78 2.29 14.59 <0.01
Dependence 1.33 0.89 1.99 0.16
Early Season 0.83 0.48 1.45 0.51
Late Season 0.89 0.65 1.2 0.44
*Adjusted odds ratio compared to referent group: female, aged 46 to 64 years, non-Māori non-Pacific ethnicity, not low income, not pregnant, non-
smoker, without chronic disease, not obese, with self-rated health average or better, not on long term oxygen use, living without assistance and 
admitted to hospital for SARI during the influenza season.
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